Retour à la page

BIBLIOGRAPHIE

1. Kannel WB, Skinner jj, schwartz mj, shurtleff d. Incidence in the FRAMINGHAM study .Circulation ,41,875-833,1970

2. Dormandy JA, Rutherford  . Management of peripheral arterial disease . TASC Working group.  Jl Vasc Surg 2000 part 2, 31(1) S1-S296.

3. Bloch C, Richard JL. Les facteurs de risque dans l'étude prospective parisienne. Comparaison avec les études étrangères. Rev Epidemiol .Santé Publique 33,108-120, 1985.

4. Dormandy JA. Epidémiologie et histoire naturelle des artériopathies des membres inférieurs. Rev Prat 1995,45:32-36

5. Meijer WT, Hoes AW, Rutgers D,Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: the Rotterdam study . Arterioscl Thromb Vasc Biol 1988;18:185-192.

6. Boccalon H, Lehert P, Mosnier M. Appréciation de la prévalence de l'artériopathie des membres inférieurs en France à l'aide de l'index systolique dans une population à risque vasculaire. J Mal Vasc 200;25:38-46.

7. Sermet C. En collaboration avec E.Grandjean .Evolution de l'état de santé des personnes âgées en France ,1970-1996. Questions en santé publique. CREDES/Les éditions INSERM. Rapport n° 1214- mars 1998-

8. Kannel WB, Shurtleff B. The natural history of arteriosclerosis obliterans  Cardiovasc.clin. 1970, 3,37-52

9. Juergens JL, Barker NW, Hines GA. Arteriosclerosis obliterans: review of 520 cases , with special reference to pathogenic and pronostic factors. Circulation 1960, 41, 875-883.

10. Ponsonnaille J, Fabry R, Chapou M, Lipiecki J, Delahaye R, Duchene-Marullaz P. Les cardiopathies ischémiques silencieuses chez l'artéritique. Dépistage et pronostic à 5 ans dans une population de 418 patients. Arch Mal Cœur ,1991,84,1407-1411

11. Rolland N, Lebrun T, Comte S, Sailly JC. Conséquences de l'artériopathie oblitérante des membres inférieurs ( AOMI) sur l'activité professionnelle des patients et sur les aides extérieures .J Mal Vasc 1999;24:208-213.

12. Capron L.  Facteurs de risque et prévention . In Médecine vasculaire : angiologie et explorations fonctionnelles vasculaires . C. Boissier, PH. Carpentier , JM. Mollard John Libbey Eurotext Paris 1995 pp.3-7.

13. Kannel WB, Mc Ghee DL. Update on some epidemiological features of intermittent claudication : the Framingham study .J.Am.Ger.Soc  1985, 33,13-18

14. Bakir R, Chanu B, Rouffy J. Epidemiologie des artériopathies oblitérantes chroniques des membres inférieurs d'origine athéromateuse. Gaz Med France 1981,88,3041-305

15. Erb W. Klinische beitrage zur pathologie des intermittierenden Hinkens.Munch Med Wochenschr 1911;2:2487

16. Fowkes GR, Housley E, Riemersma RA, Macintyre CA, Cawood EH, Prescott RJ et al. Smoking , lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ishemic heart disease in the Edinburgh Artery Study . Am J Epidemiol 1992,135:331-340.

17. CAPRIE  Steering Committee. A randomised blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events ( CAPRIE) Lancet 1996;348:1329-1339

18. Dallongeville J, Marécaux N, Fruchart JC, Amouyel P. Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta -analysis. J. Nutr. 1998 128:1450-1457

19. Ingolfsson IO, Sigurdson G, Sigvalsason H, Thorgeirsson G, Sigdusson N .A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong correlation to smoking and serum cholesterol- the Reykjavic study . J Clin Epidemiol 1994;47:1237-1243.

20. Hajek P, Taylor TZ, Mills P. Brief intervention during hospital admission to help patients to give up smoking after myocardial infarction and bypass surgery: randomised controlled trial. BMJ 2002;324:87-89

21. Beach KW, Brunzell JD, Strandness DE. Prevalence of  severe arteriosclerosis obliterans in patients with diabetes mellitus. Relation with smoking and form of therapy .Arteriosclerosis 1982,2,4:275-280.

22. Most RS, Sinnock P. The epidemiology of lower extremity amputation in diabetic individuals . Diabetes Care 1983,6,87-91.

23. Widmer LK, Da Silva A. Historical perspectives and the Basle study . In: Fowkes FGR ed.Epidemiology of Peripheral Arterial Disease .London.: Springler-Verlag ,1991:69-83.

24. Safar M. Pression pulsée et risque cardio-vasculaire . Angéiologie 2002,vol 54 n°2 13-14.

25. Haiat R, Leroy G. Dyslipidémies .Les enseignements des grands essais thérapeutiques. Editions Frison -Roche  paris 2002.

26. Gofin R, Karic JD, Friedlander Y. Peripheral vascular disease in a middle aged population sample: The Jerusalem Lipid Research Clinic Prevalence study . Int J Med 1987,23,157-67.

27. Stamler J. Research related to risk factors. Circulation 1979,60,1575-1787.

28. Rose GA. The diagnosis of ishaemic heart pain and intermittent claudication in field surveys. Bulletin of the World Health Organization  1962,27:321-346.

29. Artériopathies des membres inférieurs : dépistage et risque cardio vasculaire . Expertise collective .INSERM 1994

30. Richard JL, Ducimetière P, Elgrishi I, Gelin J. Dépistage par questionnaire de l'insuffisance coronarienne et de la claudication intermittente . Rev Epidemiol Med Soc Santé Publ 1972,20:735-755

31. Leng GC, Fowkes FGR. The Edinburgh claudication questionnaire: an improved version of the WHO/Rose questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992,45:1101-1109.

32. Dormandy JA. Palpation of peripheral pulses: a difficult art. Ann R Coll Surg Engl 1992,74:155

33. Maggee TR, Stanley PRW, Mufti RA, Simpson L, Campbell WB. Should we palpate foot pulses? Ann R Coll Surg Engl 1992,74:166-168.

34. Fowkes FGR. The measurement of atherosclerotic peripheral arterial disease in epdemiological surveys. Int J. Epidemiol 1988,17:248-254.

35. Boykio EJ, Ahroni J, Davignon D, Stensel V, Prigeon RL, Smith DG. Diagnostic utility of the History and Physical examination for peripheral vascular disease among patients with diabetes mellitus. J Clin Epidemiol.50,6:659-668.

36. Brearly S, Sheearman CP, Simms MH. Peripheral pulse palpation : an unreliable physical sign. Ann R Coll Surg Engl . 1992;74(3)169-71.

37. Lawson IR, Ingman SR, Masih Y, Freeman B. Reliability of palpation of pedal pulses as ascertained by the kappa statistic. J Am Geriatr Soc 1980;28(7):300-303.

38. Robertson GS, Ristic CD, Bullen BR. The incidence of congenitally absent foot loose. Ann R Coll Surg Engl 1990;72 (2) :99-100

39. Stegall HF, Kardon MB, Kemmener WT. Indirect measurement of arterial blood pressure by Doppler ultrasound sphygmomanometry. J Appl Physiol 1971;30:585-588.

40. Boccalon H, Lehert P. Early diagnosis of arteriopathy of the legs using measures adapted to general practitioners : the systolic index and pulse perception. J Mal Vasc 1995;20(1):28-37.

41. Cazaubon M, Paris D, Depairon  M. Problèmes irrésolus de la mesure de l'indice de pression systolique : revue de la littérature. Angéiologie 2002,vol 54, n°2, pp 27-32.

42. Simon A, Papoz L, Ponton A, Segond P, Becker F, Drouet  L, Levenson J et al. Feasibility and reliability of ankle/arm blood pressure index in preventive medecine. Angiology 2000 ;51(6):463-471.

43. Newmann AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, Wolfson SK. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study .Circulation 1993;88(3)837-845.

44. Greenland P, Abrams J, Aurigemma G,Bond G, Clark L, Criqui MH et al. Prevention conference : Identifying the high risk patient for primary prevention : non invasive test of atherosclerotic burden : writing group II. Circulation 2000:101; E 3-E11.

45. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of the ankle brachial pressure index to predict cardiovascular events and death : a cohort study . BMJ 1996 ;313:1440-1443.

46. Touboul P. Paroi artérielle et risque cardio vasculaire . Epidémiologie de l' Epaisseur Intima Média en France, relation avec les facteurs de risque d'athérosclérose. Angéiologie 2002 , 54, n°3,44-45

47. Denarié N, Simon A. Intérêt de la détection précoce de l'athérosclérose carotidienne pour stratifier le risque vasculaire. Angéiologie 1999 51, n°1 :28-34

48. Cazaubon M, Blanchemaison P. Règles de prévention en pathologie vasculaire périphérique.  Encycl Méd Chir ( Editions scientifiques et médicales Elsevier SAS , Paris , Angéiologie, 19-3680 , 2000.

49. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical pratice recommendations in the AHCPR guideline for smoking cessation.Agency for health Care Policy and research. Jama 1997;278(21)1759-66.

50 . Montron A, Guignard E, Pelc A, Comte S. Peripheral arterial obliterative disease. Cost of illness in France . Pharmacoeconomics 1998;13(1Pt1):51-9.

51. Jansen RM, De VRIES SO, Cullen KA, Donaldson MC, Hunink MG. Cost-identification analysis of revascularization procedures on patients with peripheral arterial occlusive disease. J Vasc Surg 1998;28(4):617-623.

52. Lebrun T, Selke B, Sailly JC, Boissier C, Mosnier M. The introduction of economic criteria into the management of arterial disease: an illustration with  regard to the socioeconomic consequences of peripheral occlusive arterial disease of the lower limbs. J Cardiovasc Pharmacol 1994, sup 3:S17-21.

53. EUROASPIRE I and II group. Clinical reality of coronary prevention guidelines= a comparison of EUROASPIRE I and II in nine countries. Lancet; 2001;357:995-1001.

54. Hirsch J, Hull RD, Raskob GE. Clinical features and diagnosis of venous thrombosis. J Am Coll Cardiol 1986,8:114B-127B.

55. Coon WW, Willis PW, Keller JB. Venous thromboembolims and other venous disease in the Tecumseh community health study .Circulation , 1973,48,839-846.

56. Nordström M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J. Internal .med,1992,232,155-160.

57. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population -based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism . The Worcester DVT Study . Arch Intern med 1991;151(5):933-938.

58. Even P, Sors H, Safran D, Reynaud P, Stern M, Dennewald G, Salmon O. L'embolie pulmonaire .Pièges et approche diagnostiques. In : Réanimation en médecine d'urgence. Goulon M . Ed. Expansion Scientifique Française ,1980-1981.

59. Lilienfeld  DE. Decreasing mortality from pulmonary embolism in the United States , 1979-1996. Int J of Epidemiol 2000;29:465-469.

60. Salem G. Rican S, Jougla E. Atlas de la santé en France . Volume 1. les causes de décès. Editions John Libbey Eurotext 1999.

61.  Consensus statement . prevention of venous thromboembolism . International Angiology .Vol 16 n°1, 4-38

62. Kahn S, Ginsberg J. The post-thrombotic syndrome: current knowledge , controversies and direction for future research . Blood Rev 2002, 16 (3) :155

63. Salzman EW, Hirsh J. Prevention of venous thromboembolism . In : Colman RW, Hirsh J,Marder V, Salzman EW, editors .Hemostasis and thrombosis, basic principles and clinical practive.New York:Lippincott ,1982:986.

64. Thilly N, Pierson H, Collard C, Lecompte T, Dufay E: Prevention de la maladie thrombo-embolique veineuse en milieu médical: de l'aide à la décision à l'utilisation des héparines de bas poids moléculaire. Thérapie 1998 ; 53:579-586.

65. Nicolaides AN, Irving D. Clinical factors and the risk of deep venous thrombosis .In :Thromboembolism. Nicolaides AN. (Ed) Baltimore .university Park press , 1975,193-204.

66. Ninet J, Horellou MH, Darjinoff JJ, Caulin C, Leizorovicz A. Evaluation des facteurs de risque préopératoires. Ann.Fr.Anesth.Reanim. 1992, 11, 252-281.

67. Boneu B, Schved JF, Lecompte T, Alessi MC. Recommandations du Groupe d' Etudes sur l' Hémostase et la Thrombose ( GEHT) Sang Thrombose et vaisseaux 2000, n° spécial.

68. Tribout B, Lenoir F, Gras V, Rumpala C, Andrejak M. Résistances acquises aux antivitamines K, mauvais équilibre sous anticoagulants oraux : rôle des apports alimentaires en vitamine K. Angéiologie 2001, n°3 39-48

69. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D et al. Non cardiovascular Disease Outcomes During 6, 8 years of Hormone Therapy . Heart and estrogen/Progestin Replacement Study Follow-up ( HERS II)  JAMA 2002, 288, n°1  58-66.

70. Bounameaux H, De Moerloose P, Perrier A, Reber G. Plasma measurement of D-dimer as diagnostic aid in suspected venous thromboembolism.An overview. Thromb.Haemosta.1994,71:1-6.

71. Becker F. Maladie post- thrombotique: physiopathologie, diagnostic, traitement. In maladie thrombo-embolique veineuse . Elias A. Fiessinger JN. Collection de Médecine Vasculaire 5. Masson . Paris 1995.

72. O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent M. Economic evaluation of outpatient treatment with low-molecular weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159(19):2298-2304.

73. Boccalon H, Elias A, Chale JJ, Cadene A, Gabrile S. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrénées study. Arch Intern Med 2000;160(12):1769-73.

74. Sawicki PT. A structured teaching and self management program for patients receiving oral anticoagulation .A randomized controlled trial .Working Group fir the Study of Patient Self-Management of oral Anticoagulation. JAMA, 1999; 281:145-150.

75. Schved JF, De Moerloose P, Jude B, Toulon P. Utilisation des antivitamines K en pratique médicale courante. Sang Thrombose et vaisseaux 2000, n°spécial ; 12 :26-39.

76. Dunn AS, Coller B.  Outpatient treatment of deep vein thrombosis: translating clinical trials into practive. Am J Med 1999;106(6) :660-669

77.M.Langan III, Coffey CB, Snyder BA, Sullivan TM. The impact of the development of a program to reduce urgent ( off-hours) venous duplex ultrasound scan studies. J Vasc Surg 2002;36:132-6.

78. Eklof B . Air travel related thrombo embolism. Angéiologie ,2001, vol 53, n°spécial 1 11-14.

79.Scurr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention of symptomless deep-vein thrombosis in long -haul flights : a randomised trial. Lancet 2001, 357:1485-1489

80. Cesarone MR, Belcaro G, Nicolaides AN, Incandela L,Geroulakos G, Lennox A  and col. Venous thrombosis from air-travel ; the LONFLIT 3 Study . prevention with aspirin vs low-molecular-weight heparin in high risk subjects : a randomized trial. Angiology 2002;53(1)1-6.

81. Lance G. Insuffisance veineuse chronique et varices: épidémiologie. In Collection de médecine vasculaire 2. Barthelemy P,Lefebvre D. Masson 1994 .

82. Perrin M. Classification et stades de sévérité dans les maladies veineuses chroniques des membres inférieurs. Angéiologie.1995,47, n°spécial:9-16.

83. ALLAERT FA.  Evolution of venous insufficiency according its lenght of duration . International Angiology ,vol 20, sup 1 p 114 .14 th World Congress. Union Internationale de Phlébologie . Septembre 9-14 2001, Rome Italie.

84. ALLAERT F.A, CAUSSE C:  Pharmaco - épidémiologie de la prise en charge de l’insuffisance veineuse chronique en médecine générale. Angéiologie, 2000, 52, n°4:8-16

85. Weiss RA, Duffy D. Clinical benefits of lightweight compression: reduction of venous -related symptoms by ready-to-wear lightweight gradients compression hosiery . Dermatol Surg 1999;25(9):701-704.

86. Evans CJ, Fowkes FGR, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population : Edinburgh Vein Study . J Epidemiol Community Health 1999;53 :149-153.

87. GRITON P : Conceptions étiopathogéniques des télangiectasies. In: DAVY A, Van DER STRICHT J. Phlébologie 1983,2:686-7 , Bruxelles, Ars Medici, 1983.

88. Bihari I, MagyarF. Microshunt in telangiectias . Int J Angiol 1999;8:98-101.

89. Benigni JP, Sadoun S. Telangiectasia:Benefits of a foam sclerosing agent. Journal of Phlebology . 2002; 2:35-49.

90. Goldman MP. Sclerotherapy treatment of varicose and telangiectasia. Mostby Yearbook Pub. St Louis. 1991.

91. Levy JL, Elbhar C, Pizzi M. Résultats des lasers vasculaires sur les télangiectasies des membres inférieurs . Phlébologie 2001, 54, n°4, 413-416.

92. Brand FN, dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins : the Framingham Study . Am J Prev Med  1988, 4:96-101

93. Cesarone MR, Belcaro G, Nicolaides AN, Geroulakos MD, Griffin M. "Real" -Epidemiology of varicose veins and chronic venous diseases . The San Valentini vascular sreening project.

94. CORNU THENARD A, BOIVIN P, BAUD JM . Importance of the familial factor in varicose disease: clinical study of 134 families. J Dermat.Surg.Oncol. 1994;20:318-26

95. SCHADECK M. Maladie veineuse chronique : dépistage précoce chez l'enfant et l'adolescent.  Angéiologie 2000, vol 52 n°2 77-79

96. Cordts PR, Gawley TS. Anatomic and physiopathologic changes in lower extremity venous hemodynamics associated with pregnancy . J.Vasc.Surg. 1996, 24:763-767.

97. Dindelli M, Parazzini F, Basellini A, Rabaiotti E, Corsi G, Ferrari A. Risk factors for varicose disease before and during pregnancy . Angiology 1993 ;44 (5) :361-367

98. ESTRYN BEHAR M. BERTHIER C, GOZLAN C, CLOAREC M. Apport de l’ergonomie à l’étude épidémiologique de la maladie veineuse superficielle. Phlébologie 1998 , 51 n°1 15-19.

99. Fowkes FGR, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population : Edinburgh Vein Study  Int J  Epidemiol . 2001;30:846-852

100. KRIJNEN RM, BOER EM, ADER HJ, BRUYNZEEL DP. Venous insufficiency in male workers with a standing profession , part 1 and 2 .Dermatology ,1997;194:111-126.

101 . TUCHSEN F, GRAUSE N, HANNERZ H, BURR H, KRISTENSEN TS Standing at work and varicose veins. Scand J Work Environ Health 2000 ;26(5):414-20

102. CHAM R, REDFERN MS. Effect of flooring on standing comfort and fatigue. Hum Factors 2001; 43(3):381-91.

103. Gourgou S, Dedieu F, Sancho-Garnier H. Lower-limb venous insufficiency and tobacco smoking: a case control study. Am J Epidemiol 2002;155(11):1007-1015.

104. Perrin M. Un procédé nouveau dans le traitement des varices des membres inférieurs : la technique Closure ®.Angéiologie , 2000,52, n°4 23-28.

105. Perrin M. Chirurgie de l'insuffisance veineuse superficielle. Encycl Med Chir (Paris-France) .Techniques chirurgicales- Chirurgie Vasculaire 43-161 A ,1995, 26 pages.

106. Perrin M. Cure chirurgicale des varices des membres inférieurs par stripping des veines saphènes. Ann Chir ,1997, 51, n°7,735-744.

107. Perrin MR, Guex JJ, Ruckley CV, de Palma RG, Royle JP,Eklof B, Nicolini P.  Recurrent varices after surgery ( REVAS) a consensus document. REVAS Group. Cardiovasc Surg 2000, 8(4):233-45.

108. Guex JJ, Isaacs MN. Comparison if surgery and ultrasound guided sclerotherapy for treatment of saphenous varicose veins: must the criteria for assessment be the same? Int Angiology, 2000,19(4) 299-302.

109. Chandler JG, Pichot O, Sessa C, Schuller-Petrovic S, Kabnik LS, Bergan JJ. Treatment of primary Venous Insufficiency by Endovenous Saphenous Vein Obliteration. Vasc Surg 2000;34:201-214.

110. Cost of venous diseases. Rapport du Centre de Recherches Economiques Sociologiques et de Gestion . CRESGE. Lille 1991.

111. Dépenses de santé. In Cluzeau C, Dubeaux D.( Eds) Tableau de l'économie française .Paris INSEE,1997 p:64.

112. Agache P. Pathogénie des ulcères de jambe d'origine veineuse. Angéiologie 1998,50 n°1 ,11-27.

113.  Nelsen O, Bergqvist D, Lindhagen A. Leg ulcer etiology : a cross sectional population study . J Vasc Surg 1991;64, 14, 557-564.

114. Nelzen O, Bergqvist D, Lindhagen A. Venous and non-venous leg ulcers: clinical history and appearance in a population study. Br J Surg 1994;81(2):182-187.

115. Ruckley CV. Socioeconomic impact of chronic venous insufficiency and leg ulcers. Angiology 1997;48(1):67-69.

116. Fowkes FGR, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency . Angiology, 2001, 52,sup.1, S5-S15.

117. Walker N, Rodgers A, Birchall N, Norton R, Mac Mahon S. The occurence of leg ulcers in Auckland : results of a population-based study. N Z Med J. 2002; 115(1151):159-162.

118. Cornwall JV, Doré CJ, Lewis JD. Leg ulcers: Epidemiology and aetiology . Br J Surg 1992,79:1032-1034.

119. Strandness DE, Langlois Y, Cramer M, Randlett A, Thiele BL. Long-term sequelae of acute venous thrombosis. JAMA,1983;250(10):1289-1292

120. Lindner DJ, Edwards JM, Phinney ES, Taylor LM, Porter JM. Long term hemodynamic and clinical sequelae of lower extremity deep vein thrombosis. J Vasc Surg 1986,4(5):436-442.

121. Barras JP, Widmer MT, Zemp E, Voilin R, Widmer LK. Séquelles de la thrombose veineuse . Incidence à 5 ans du syndrome post-thrombotique . J Mal Vasc 1991,16,115-118.

122. Maessen -Visch MB, Hamulyak K, Tazelaar DJ, Crombag NH, Neumann HA. The prevalence of factor V Leiden mutation in patients with leg ulcers and venous insufficiency . Arch Dermatol 1999;135(1):41-44

123. Hafner J, Kuhne A, ScharB, Bombeli T, Hauser M, Luthi R, Hanseler E. Factor V Leiden in postthrombotic and non post thrombotic venous ulcer. Arch Dermatol. 2001;137(5):599-603.

124.Mackenzie RK, Ludlma CA, Ruckley CV, Allan PL, Burns P, Bradbury AW. The prevalence of thrombophilia in patients with chronic venous leg ulceration. J Vasc Surg 2002,35(4):718-722.

125. Ribeaudeau F, Senet P, Cayuela JM, Fund X, Paul C, Robert C, Scrobohaci ML, Dubertret L. A prospective coagulation study including resistance to activated protein C and mutations in factor V and II in venous leg ulcers. Br J Dermatol 1999;141(2):259-263.

126 . Bergqvist D, Lindholm C, Nelzen O.Chronic leg ulcers : The impact of venous disease. J Vasc Surg 1999; 29:752-755.

127. Baccaglini U, Giraldi E, Spreafico G, Castoro C, Sorrentino P, Baggio E, Lipari G, Maletti O. Etude multicentrique sur les ulcères veineux en Italie : les ulcères rebelles . Phlébologie Annales vasculaires 1997,50 , n°3 :371-378.

128. Nelzen O, Bergqvist D, Lindhagen A. Long term prognosis for patients with chronic leg ulcers : a prospective cohort study. Eur.J.Vasc.Endovasc.Surg 1997;13:500-508

129. Allaert FA, Quantin C. Approche méthodologique de la création et de la validation d'une échelle de risque des ulcères variqueux. Angéiologie . 1999,51 , n°4 82-85.

130.Jacob MP, Cazaubon MC, Scemama A, Prie D, Blanchet F, Guillin MC, Michel JB. Plasma matrix metalloproteinase -9 as a marker of blood stasis in varicose veins. Circulation. 2002,30;106(5):535-538.

131.Traitement compressif des membres . Partsch H. Rabe E, Stemmer R. Editions Phlébologiques Françaises .janvier 2000.

132. Ulcère de jambe . In Ramelet AA, Monti M. Phlébologie . Abrégés Masson 4 ème édition . Paris 1999.

133. Smith JJ, Guest MG, Greenhalg RM, Davies AH. Measuring quality of life in patients with venous ulcers. J Vasc Surg 2000;31:642-9.

134. Levy E,Lévy P. Les attitudes thérapeutiques des médecins français face à l'ulcère veineux de jambe : diversité et coûts induits. L Mal Vasc 2001;26:39-44.

135. Olin JW, Besterien KM, Childs MB, Seavy C, McHugh L, Griffiths RI. Medical costs of treating venous stasis ulcers:evidence from a retropsective study. Vasc Med 1999;4(1)1-7.

136. LAFUMA A, FAGNANI F, PELTIER-PUJOL F, RAUSS A : La maladie veineuse en France:un problème de santé publique méconnu. J Mal Vasc 1994; 19:185-9

137. RUCKLEY C.V: Socio-economic impact of chronic venous insufficiency and leg ulcer. Angiology. 1997, 48(1)-67-69.

138. Morrell CJ, Walters SJ, Dixon S, Collins KA, Brereton LML, Peters J, Brooker CG. Cost effectiveness of community leg ulcer clinics: randomised controlled trial . BMJ 1998;316:1487-1491.

138. Gjores JE. Symposium on venous leg ulcers. In Acta  Chir Scan 1988.  Suppl.544,7-8.

139. Wienert V: Epidemiologie et socio-économie des maladies veineuses en Allemagne. Phlébologie, 1993, 46::225-234

140. Van der Oever R, Hepp B, Debbaut B, Simon I. Socio-economic impact of chronic venous insufficiency . An underestimated public health problem. Int Angiol 1998;17(3):161-167.

141. Causse C, Allaert FA, Cazaubon M. Validation d'un observatoire épidémiologique et pharmaco-économique de la maladie veineuse . Angéiologie, 2002, 54 n°3: 130-136

142. FLOURY N.C, GUIGNON N, PINTEAUX A: Données sociales 1996. La Société Française .Editions INSEE. Paris 1996.

143. Da Siva A, Navarro MF, Batalheiro J. The importance of chronic venous insufficiency . Various premilinary data on its medico-socail consequences . Phlébologie 1992;45(4):439-443.

144. Dale JJ, Ruckley CV, Harper DR, Gibson B, Nelson EA, Prescott RJ. Randomised , double blkind placebo controlled trial of pentoxifylline in the treatment of venous leg ulcers; BMJ,1999;319:875-878.

145. Howar s A, Davies AH .  Qualité de vie liée à la santé chez des patients présentant un ulcère veineux . Phlebology  2001;16:12-16

146. Launois R, Reboul-Marty J, Henry B. Construction and validation of a quality of life questionnaire in Chronic Lower Limb Venous Insufficiency. Quality of Life research. 1996,5:539-554.

147. Copenhagen WHO Regional Office for Europe 1998. Therapic patient education: continuing education programmes for health care providers in the field of prevention of chronic diseases : report of a WHO working group. Recommandations d’un groupe de travail de l’ O.M.S. Bureau régional pour l’ Europe, Copenhague:11-14juin 1997.

148. Ministère de la Santé. Loi n° 98-1194 du 23 décembre 1998.

149. BRODIN M. Rapport pour la Conférence Nationale de la Santé . Paris 21 au 23 mars 2000)

150. SATGER B., CARPENTIER P-H, POENSIN D, FECHOZ C, COLOMB M, KALINOWSKI I. « L’école de la veine «  Un programme d’éducation pour les patients atteints d’insuffisance veineuse chronique à la station thermale de La Léchère . J Mal Vasc 2002;27:26-30.

151. Vray M, Chwalow J, Charansonnay O, Vasmant D, Capron L, Boccalon H, Eschwege E. National study of obliterative artérial disease of the lower limbs involving general practitioners in France : Artemio study. Journal of Cardiovascular Pharmacology .1995  vol 25 ( sup.2): S1- S 57 .

152. Nault P. Agrément des laboratoires vasculaires en Amérique du Nord . Angéiologie 2001,53,n°3,87-89

Retour à la page